Ziga Rotar

Ljubljana, 1000, Slovenia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 119 publications

Malnutrition and sarcopenia in rheumatoid arthritis: Prevalence, risk factors, and the limitations of body mass index: A cross-sectional study.

Malnutrition and sarcopenia in rheumatoid arthritis: Prevalence, risk factors, and the limitations of body mass index: A cross-sectional study.

Journal: Clinical nutrition ESPEN

Published: July 19, 2026

The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.

The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.

Journal: EULAR rheumatology open

Published: June 29, 2026

Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study.

Differential joint-level response to secukinumab in psoriatic arthritis: A collaborative European observational cohort study.

Journal: EULAR rheumatology open

Published: June 29, 2026

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Overall and Sex-Specific Predictors of Secukinumab Effectiveness in European Patients With Psoriatic Arthritis: Results From the EuroSpA Collaboration.

Journal: The Journal of rheumatology

Published: June 15, 2026

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Overall and sex-specific predictors of secukinumab effectiveness in European patients with psoriatic arthritis: results from the EuroSpA collaboration.

Journal: The Journal of rheumatology

Published: June 15, 2026

Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project.

Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project.

Journal: Annals of the rheumatic diseases

Published: February 19, 2026

Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries.

Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countries.

Journal: Annals of the rheumatic diseases

Published: February 11, 2026

Defining and validating a high specificity MRI cut-off for the radiographic part of the modified New York criteria in patients with axial spondyloarthritis.

Defining and validating a high specificity MRI cut-off for the radiographic part of the modified New York criteria in patients with axial spondyloarthritis.

Journal: Arthritis research & therapy

Published: January 06, 2026

The Societal and Patient-Level Burden of Sickness Absenteeism in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Across Two Decades in Slovenia.

The Societal and Patient-Level Burden of Sickness Absenteeism in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Across Two Decades in Slovenia.

Journal: Zdravstveno varstvo

Published: November 19, 2025

Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.

Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.

Journal: RMD open

Published: October 28, 2025

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration.

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 20, 2025

Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings.

Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings.

Journal: Seminars in arthritis and rheumatism

Published: October 02, 2025

Showing 1-12 of 119

Last Updated: 09/26/2026